The molecule
Semaglutide is a 31-residue analogue of native GLP-1 with two key modifications: an aminoisobutyric-acid substitution that resists DPP-4 cleavage, and a C18 fatty-diacid side chain that binds serum albumin. Together these give it a circulating half-life of roughly one week in humans.
The molecular formula C₁₇₂H₂₆₅N₄₃O₅₁ and molecular weight of 4113.6 g/mol place it firmly in the large-peptide category, but its receptor selectivity is remarkably clean — activation at GLP-1R without meaningful engagement of GIP or glucagon receptors.
Receptor binding profile
Radioligand displacement studies place semaglutide's EC50 at GLP-1R in the low picomolar range. Downstream cAMP accumulation curves are steep and reproducible, which is what makes it the reference tool for isolating GLP-1-specific effects.
For researchers designing comparative experiments, semaglutide functions as a control against which dual and triple agonists can be benchmarked without ambiguity.
Half-life in context
The extended half-life is not always desirable in research. For short-window studies, the compound's persistence in circulation complicates crossover designs. In those cases, native GLP-1 or short-acting exenatide fragments remain the correct tools.
Reproducibility notes
Semaglutide's synthesis is well-optimised across suppliers, and inter-lot variation is generally low. Verify each lot with HPLC purity ≥98% and mass spectrometry confirmation before committing to a longitudinal study.